Our aim was to evaluate the efficacy and safety of neoadjuvant chemotherapy followed by radical hysterectomy and adjuvant radiation concurrent with weekly cisplatin for locally advanced cervical carcinoma.
Introduction
Cervical carcinoma is still one of the most frequent and lethal malignancies in women worldwide [1] . For early stages of the disease, surgery and/or radiation are effective treatment modalities [2] ; however, the treatment of locally advanced cases is suboptimal.
Earlier attempts to improve the prognosis of these patients included the use of neoadjuvant chemotherapy followed by radiation. However, this sequential modality failed to improve the prognosis, most probably because of the cross-resistance between chemotherapy and radiation [3] . More recently, seven of eight prospective randomized phase III trials have shown the superiority of chemotherapy delivered concurrently with radiation, compared with standard radiation [4] [5] [6] [7] [8] [9] [10] [11] . Nevertheless, the absolute benefit in survival is only 12% according to a meta-analysis of concurrent chemoradiation trials [12] .
On the other hand, several studies have evaluated the role of radical surgery after neoadjuvant chemotherapy. The main rationale of this approach is that surgery may bypass the cross-resistance between chemotherapy and radiation delivered sequentially; thus the disease remaining after chemotherapy could in theory be more effectively treated with surgery. Interestingly, phase III randomized trials demonstrate the superiority of this neoadjuvant approach over radiation alone [13] [14] [15] . However, because of the superiority of concurrent chemoradiation over radiation alone [12] , neoadjuvant chemotherapy should now be compared with standard chemoradiation. Pending confirmation from prospective randomized phase III trials, data from two consecutive phase II studies comparing neoadjuvant chemotherapy and surgery versus standard chemoradiation suggest that both modalities are similar in terms of survival [16] . Even assuming that these two modalities are equally effective, newer approaches should be tested in order to improve the prognosis of locally advanced cervical cancer patients.
In order to get the maximum benefit from the neoadjuvant chemotherapy and surgery modality there are two issues that should be addressed. One is to determine the optimal management of patients who do not achieve a major response to induction chemotherapy, and are therefore not able to undergo radical hysterectomy. These patients are usually treated with radiation alone and have a poor prognosis, compared with those able to undergo surgery [17] [18] [19] [20] . Thus, maximum effort should be made to submit these patients for surgery, as the tumor cells remaining after induction chemotherapy will most likely be resistant to radiation. Nevertheless, despite the use of a highly active program of induction chemotherapy, a proportion of patients cannot undergo surgery and the use of chemoradiation instead of radiation alone as local treatment might have a good chance of control [21] . A second issue is to prevent the failures in patients who undergo radical hysterectomy. In a literature review of all trials of neoadjuvant chemotherapy and surgery, some patients have been treated with adjuvant pelvic radiation [22] ; however, the benefit of adjuvant radiation in this setting is yet to be proved [23] . In contrast, the single study reported of concomitant adjuvant chemoradiation has shown positive results [4] , which makes it logical to employ concurrent chemoradiation instead of radiation alone as adjuvant treatment for the locally advanced cases submitted to induction chemotherapy and surgery. In this regard, we have previously reported that postoperative chemoradiation is feasible in this patient population [24] .
We report the results of a phase II trial of multimodality treatment of locally advanced cervical carcinoma using carboplatin and paclitaxel as neoadjuvant chemotherapy, followed by radical surgery and adjuvant cisplatin chemoradiation.
Patients and methods
Forty-three untreated patients with histological diagnosis of cervical carcinoma of the non-small cell type (squamous, adenosquamous and adenocarcinoma) were included in this phase II study. Inclusion criteria were as follows: (i) clinically staged as IB2-IIIB according to the International Federation of Gynecology and Obstetrics (FIGO); (ii) bidimensionally measurable lesion; (iii) aged between 18 and 70 years; (iv) performance status 0-2 according to Word Health Organization (WHO) criteria; (v) normal hematological, renal and hepatic function as determined by a hemoglobin ≥9 g/dl, leukocyte count >4000/mm 3 and a platelet count of at least 100 000/mm 3 , total bilirubin <1.5 × normal upper limit (NUL), transaminases <1.5 × NUL, and normal levels of creatinine in serum; (vi) a normal posteroanterior chest X-ray; and (vii) signed written informed consent. Exclusion criteria included: (i) severe systemic or uncontrolled disease (infection, central nervous system, metabolic, etc.) that precluded the use of chemotherapy; (ii) pre-existing neuropathy of any cause; (iii) pregnancy or lactation; (iv) mental illness; and (v) previous or concomitant malignancies except non-melanoma skin cancer. The protocol was approved by the regulatory boards of the Instituto Nacional de Cancerología.
Clinical staging was performed by a multidisciplinary team of physicians (at least three examiners to reach consensus) and included pelvic examination, drawing a detailed map of the lesion, chest X-ray, cystoscopy, rectosigmoidoscopy and intravenous pyelogram. The status of the para-aortic lymph nodes was not assessed. During neoadjuvant chemotherapy, complete blood cell counts and biochemical profiles were performed at days 14 and 21 of each of the three cycles.
Treatment consisted of intravenous carboplatin at a dose giving an area under the time-concentration curve of 6 mg⋅min/ml (based on calculated creatinine clearance) diluted in 500 ml 5% glucose administered over 1 h, followed by paclitaxel at 175 mg/m 2 administered over 3 h, both drugs on day 1. Conventional premedication for paclitaxel was used. A total of three 21-day courses were administered. Chemotherapy was withheld in case of disease progression. In both cases, patients were taken to immediate locoregional treatment. Dose modifications were not allowed but could be delayed for 1 week when the platelet and neutrophil counts were <100 000/mm 3 or <1500/mm 3 , respectively. Patients could receive full supportive care, including transfusions (to keep hemoglobin ≥9 g/dl), antibiotics, antiemetics, steroids, antidiarrheals and analgesics when appropriate. The prophylactic use of colonystimulating growth factors was not allowed.
Patients who received at least two courses of chemotherapy were evaluated for response to neoadjuvant chemotherapy. This was performed at the end of chemotherapy using standard criteria. Complete response was defined as the complete disappearance of all measurable disease. Partial response was recorded as >50% reduction in the product of the two longest perpendicular diameters of all measurable lesions. No response or stable disease was defined as <50% decrease in the product of the two longest perpendicular diameters of the measurable lesions. Progressive disease was defined as >25% increase in the product of the two longest perpendicular diameters of one measurable lesion (even with the regression of other lesions) or the appearance of new ones. The evaluation was performed by three examiners.
After neoadjuvant chemotherapy all patients except those with progression to neoadjuvant treatment were submitted to radical type III hysterectomy. Patients in whom hysterectomy was not performed received definitive standard pelvic radiation with external beam (50 Gy, 2 Gy daily from Monday to Friday) and one or two applications of brachytherapy with cesium sources to deliver at least 85 and 55 Gy to points A and B, respectively, plus concomitant 6-weekly doses of cisplatin at 40 mg/m 2 during external beam radiation. Postoperative chemoradiation was performed in all cases with positive surgical margins, one or more positive pelvic lymph node and those with disease in parametria (high-risk factors for recurrence), as well as those cases whose residual disease contained vascular or lymphatic permeation and/or deep of invasion to the middle or internal thirds of the cervical stroma (intermediate-risk factors for recurrence). In the adjuvant setting, the dose of pelvic external beam radiation was 50 Gy followed by a 30-35 Gy dose to the vaginal mucosa using intravaginal brachytherapy with cesium sources. Cisplatin was administered during external radiation as described above. During chemoradiation (definitive or adjuvant), complete blood cell counts and serum creatinine were performed weekly. Transfusions were allowed to keep hemoglobin ≥9 g/dl. Toxicity to neoadjuvant chemotherapy and chemoradiation were evaluated according to the WHO and Radiation Therapy Oncology Group criteria, respectively.
Follow-up procedures included pelvic examination and vaginal cytology starting 3 months after the completion of all treatment and every 3 months thereafter. Computed tomography scans and other image studies were performed as indicated.
Survival was considered from the date of diagnosis until death or last visit. Survival curves were constructed according to the Kaplan-Meier estimator [25] .
Results

Characteristics of patients
Between December 2000 and June 2001, 43 patients were enrolled in this study. Patient characteristics are shown in Table 1 . The median patient age was 45.7 years (range 24-67), most patients had squamous tumors (81.4%) and 49% were staged as IIB, 35% as IB2-IIA and 16% IIIB. All patients were evaluated for response and toxicity to chemotherapy. A total of 129 courses of chemotherapy were administered.
Clinical response to neoadjuvant chemotherapy
Objective responses were recorded in 41 patients (95%) [95% confidence interval (CI) 89.2% to 100%); of these, four (9%) were complete and 37 (86%) were partial. Two patients (5%) showed no response to chemotherapy (Table 2 )
Local treatment
After induction chemotherapy, all but two patients underwent radical hysterectomy. In one patient, a protocol violation occurred and an anterior exenteration was performed. In two patients, surgery was not performed because of no response to neoadjuvant chemotherapy; both progressed to definitive chemoradiation. Overall, the resectability rate was 95% (41 of 43). The analysis of the surgical specimens showed complete pathological response in seven of 41 patients (17%) who underwent resection. Microscopic residual disease with no high or intermediate-risk factor for recurrence (near-complete response) was found in eight (20%); partial pathological response (response less than near-complete) was found in 26 of 41 patients (63%). Out of 41 operated patients, positive surgical margins were found in five (12%) and pelvic lymph node positivity in eight (20%). The average of resected pelvic lymph nodes per patient was 20.4 (11-53), and 13 of 837 nodes (1.5%) were positive. Accordingly, 15 patients (37%) did not require adjuvant treatment (seven complete and eight nearcomplete pathological response). Thus, 26 patients (63%) were scheduled for adjuvant chemoradiation; however, three patients refused additional treatment, one refused concurrent cisplatin and received only radiation. In total, 22 of 41 operated patients went on to adjuvant chemoradiation and completed treatment. The mean dose of external radiation was 49.3 Gy (range 46-56), which was delivered in 43 days (range 33-61). The mean actual dose of brachytherapy delivered was 32 Gy (range 25.5-35.6). The median number of weekly courses of cisplatin delivered was five (range two to six). With regard to the time needed to deliver the treatment, neoadjuvant chemotherapy was completed in 74 days (range 59-106) and neoadjuvant chemotherapy and surgery in 93 days (77-127), whereas it was 166 days (111-237) for neoadjuvant chemotherapy and surgery and adjuvant chemoradiation.
The overall treatment and final responses of patients are shown in Table 3 .
Toxicity to induction chemotherapy
Induction chemotherapy was well-tolerated. A total of 129 cycles were administered, of which only two were delayed for 1 week. As shown in Table 4 , the most common toxicities were nausea/ vomiting and neuropathy, which were mostly grades 1/2 and occurred in 48% and 38%, respectively. There were no cases of leukopenia grade 3, but neutropenia grade 3/4 was present in 12% and 3% of courses, respectively. Other toxicities were mild and uncommon.
Surgical complications
No major surgical complications were reported. The mean duration of surgery was 4.3 h and the mean estimated blood loss was 630 ml (range 225-950). The median hospital stay was 5.7 days (range 4-8).
Toxicity to chemoradiation
Chemoradiation was well tolerated. Table 5 shows that the most frequent toxicity was leukopenia grade 1 in 44% of patients, grade 2 in 35% and grade 3 in 6%. Neutropenia grade 1, 2 and 3 was present in 29%, 24% and 6% of patients, respectively. Thrombocytopenia grades 1 and 2 were observed in 11% and 6%, respectively. Grade 3 upper and lower intestinal toxicities were observed in 6% and 18% of patients, respectively. Genitourinary and skin toxicity were mainly grade 1/2. A the time of this analysis none of the patients has presented late toxicity. 
Response after complete treatment and follow-up
A total of 41 of 43 patients underwent surgery and two received definitive chemoradiation. Overall, four patients failed to comply with all treatment (three refused adjuvant chemoradiation and one refused cisplatin during adjuvant radiation). At a median followup of 21 months (range 3-26) there have been nine events (Table  6) . Four patients have died from disease that either progressed during adjuvant or definitive chemoradiation, and one had persistent disease after neoadjuvant chemotherapy, surgery and chemoradiation and went to pelvic exenteration and had negative surgical margins but died from surgical complications.
The remaining four patients have relapsed and died; two with pelvic/systemic relapse, one with local recurrence (pelvic) and one with intra-abdominal recurrence. All operated patients who have progressed or died of recurrent disease showed only partial pathological response (macroscopic residual tumor, positive pelvic nodes or positive surgical margins. In the intention-to-treat analysis, the projected overall survival is 79% (95% CI 62% to 88%) (Figure 1 ). Currently, all living patients are disease free.
Discussion
At present, the results of treatment of locally advanced cervical carcinoma are still suboptimal due to a high rate of pelvic failures with or without a systemic component. In an attempt to improve these results, chemotherapy as a sensitizer of radiation therapy has been added. This combined approach has shown a definitive, albeit modest, gain in absolute survival that stands at 12% according to a recent meta-analysis [18] . Thus, other therapeutic options are clearly needed.
In this study, we report the results of a multimodality treatment incorporating neoadjuvant chemotherapy, radical surgery and adjuvant chemoradiation for previously untreated locally advanced cervical carcinoma. Our results suggest that this approach is feasible, produces manageable toxicity and is promising.
Neoadjuvant chemotherapy has become the standard of care or a promising modality in several solid tumors, but in cervical carcinoma it remains an experimental therapy. In this tumor type, the modality of local treatment after induction chemotherapy used is important. Despite the lack of randomized trials comparing radiation with radical surgery after induction chemotherapy, emerging data from a large number of neoadjuvant trials suggest that surgical resection could be better as it bypasses the cross-resistance between chemotherapy and radiation [17] [18] [19] [20] . Previous studies have shown that the resectability of locally advanced cervical tumors depends very much on the response to induction chemotherapy [22] . Also, the benefit on survival of neoadjuvant chemotherapy in solid tumors is mostly limited to patients with complete clinical or pathological response; therefore, the employment of an effective induction scheme of chemotherapy seems necessary in order to obtain better survival figures [26] [27] [28] .
In this study, we combined the use of carboplatin and paclitaxel. This scheme has not been tested previously in cervical carcinoma, but it is known that both agents have a high cytotoxic activity as single agents in preclinical and clinical studies of cervical cancer [29] [30] [31] [32] . On the other hand, the combination of cisplatin and paclitaxel has demonstrated significant activity in cervical cancer patients with advanced or recurrent disease achieving response rates between 40% and 50% [33] [34] [35] . Here we decided to use carboplatin instead of cisplatin because both have comparable activity against cervical cancer cells [29] , carboplatin has a more favorable toxicity profile and because cisplatin was to be used concurrently with radiation in the postoperative setting. The results of this study show that when used as first-line treatment this combination is highly active, with a 95% overall response rate, although only four cases had complete clinical response. Interestingly, there was a lack of concordance between the clinical and pathological assessment of the response as we observed in a previous study using gemcitabine-cisplatin [36] . Thus, seven (17%) and eight (20%) of the patients showed complete or near-complete pathological response, respectively. These results compare favorably with earlier regimes such as cisplatin-vincristine-bleomycin; cisplatin-bleomycin, cisplatin-ifosfamide, and many others [22] , as well as with new combinations such as cisplatin-navelbine [37] and cisplatin-irinotecan [38] in untreated cervical carcinoma patients. The combination of cisplatin and paclitaxel has been tested in advanced or recurrent cervical carcinoma yielding response rates between 45% and 47%, which are clearly inferior to the present rates, but these results are not comparable, due to differences in the treated patient population. There has only been one study of cisplatin, ifosfamide and paclitaxel performed in untreated patients [39] . Zanetta et al. [39] reported the treatment of 37 patients with locally advanced disease, most IB2/IIA, using three 21-day courses of paclitaxel 175 mg/m 2 given over 3 h on day 1, cisplatin 50 mg/m 2 (75 mg/m 2 in 10 patients), ifosfamide 5 g/m 2 in a 24-h continuous infusion and mesna. The overall clinical response rate was 84% and the pathological responses in 34 patients who underwent surgery were 16% and 18% pathological and near-complete pathological complete responses, which are almost identical to the present study. However, this three-drug combination proved to be more toxic with grade 3/4 neutropenia and thrombocytopenia in 71% and 10.5% of cases, respectively. Thus, our results confirm that the combination of carboplatin and paclitaxel is very active and devoid of significant toxicity in the neoadjuvant setting. The rationale for the use of surgical consolidation after induction chemotherapy is to avoid the cross-resistance between chemotherapy and subsequent radiation; therefore, every effort should be made to operate on patients with a poor response to induction chemotherapy. However, response to chemotherapy is not the sole factor determining operability; the 'aggressiveness' of the surgical team also plays an essential role. In our previous studies of neoadjuvant chemotherapy the operability rate was between 60% and 70% [24, 36] ; here we were able to perform radical hysterectomy in 95% of cases. This high surgical rate was due to the fact that operability was defined intraoperatively; thus some cases with partial response to chemotherapy that preoperatively looked inoperable by pelvic examination were actually able to be resected.
The role of adjuvant or postoperative radiation or chemoradiation is well-determined in early-stage patients treated by [23] . On the other hand, in high-risk (node-positive, parametrial infiltration and positive surgical margins) adjuvant concurrent chemoradiation prolongs survival compared with radiation alone [4] . However, in locally advanced patients who have received preoperative chemotherapy, the role of adjuvant treatment is yet to be determined. Sardi et al. reported a benefit in survival in two separate studies for patients in stages IIB [13] and IIIB [14] in which they used adjuvant radiation for all operated patients, whereas the results from the Italian group who only used adjuvant radiation in a subset of patients showed no significant difference in IIIB patients [15] . These results suggest that adjuvant radiation may play a role, which could be even greater if radiation were administered with concurrent chemotherapy. In a previous study by our group, in which patients were treated with neoadjuvant gemcitabine-cisplatin followed by surgery, among the 23 patients who underwent radical type III hysterectomy, six achieved a complete pathological response, three showed a microscopic residue and the remaining 14 displayed macroscopic tumor in the surgical specimen [40] . All these patients were left with no additional treatment at a median follow-up of 26 months [36] ; most of the relapses (16 of 17) have occurred in the group with macroscopic residual disease. Based on this, in the present study we treated with adjuvant radiation concomitant with weekly cisplatin all patients except those with complete or near-complete pathological response. Adjuvant chemoradiation in this setting proved to be well-tolerated with no unexpected acute toxicity. Moreover, so far none of the patients has presented late toxicity.
The follow-up of this study is rather short; however, the figure of 79% survival is encouraging. However, it is remarkable that even with this aggressive multimodality treatment that may overtreat some patients, nine patients died of either progression or relapse. This underscores the fact that locally advanced cervical carcinoma is a very aggressive disease that may require the combination of the three main therapeutic modalities presently available.
Finally, it is important to consider that the biological behavior of cervical carcinoma may differ among populations from different geographical areas, this phenomenon being linked to the association of this tumor with the human papilloma virus [41] . Thus, it seems desirable that the treatment of cervical cancer should be tailored to the different populations according to their specific tumors' biological characteristics.
